What was recalled
This page synthesizes the framework around phosphatidylserine in commercial pet food. Phosphatidylserine is a glycerophospholipid with serine attached to the phosphate head group; in cellular membranes the lipid is asymmetrically distributed to the inner leaflet through the action of ATP-dependent translocases (P4-type ATPases). PS asymmetry is biologically critical: PS exposure on the outer leaflet is a recognition signal for apoptotic cell clearance by macrophages. In neuronal physiology, PS participates in membrane fluidity (affecting receptor function and ion channel gating), serves as a cofactor for several signal-transduction kinases (protein kinase C, Raf-1, AKT/PKB), and modulates neurotransmitter release through synaptic vesicle fusion machinery. Cerebral cortex PS content declines with age in mammals; the decline is more pronounced in neurodegenerative disease states. The therapeutic supplementation rationale rests on restoring tissue PS content through dietary or supplemental intake.
Commercial PS source chemistry has shifted dramatically over the past two decades. Bovine-brain-derived PS dominated the early human supplement market because brain tissue is the richest natural PS source; following the bovine spongiform encephalopathy (BSE) epidemic in the United Kingdom in the 1990s and subsequent international regulatory action, bovine-brain-derived PS was withdrawn from supplement markets in essentially all jurisdictions by the early 2000s. Soy lecithin-derived PS is now the dominant commercial source: soy lecithin (rich in phosphatidylcholine) is enzymatically processed using phospholipase D in the presence of L-serine to convert phosphatidylcholine to phosphatidylserine. The product is purified and standardized to PS percentage. Krill oil naturally contains PS alongside omega-3 EPA/DHA and the antioxidant astaxanthin; krill-derived PS is included in some marine-source senior wellness formulations. Sunflower-lecithin-derived PS is an emerging alternative for soy-allergen-avoidance formulations.
Why it was recalled
The structural framework has two layers. Layer one — evidence base in dogs: the most-cited companion-animal evidence is Pan et al. (Br J Nutr, 2010), a controlled trial in older dogs administered a phosphatidylserine-containing supplement compared to placebo over multiple months. The trial showed modest improvements in age-associated cognitive testing performance. Subsequent canine cognitive-support work has typically used multi-ingredient formulations (PS plus DHA plus antioxidants plus medium-chain triglycerides plus B-vitamins) where attributing effect to any single ingredient is difficult. The Pan 2010 PS-specific evidence is consistent with the much larger human PS literature for age-associated cognitive support and dementia adjunct. The companion-animal evidence base supports modest inclusion in cognitive-support framework but does not support PS as a stand-alone therapy for canine cognitive dysfunction syndrome (CDS). The veterinary diagnostic and treatment framework for CDS continues to develop; PS is one of multiple supplements with mechanistic plausibility and modest evidence.
Layer two — source-stream transition and current safety: the historical BSE-risk concern for bovine-brain-derived PS is fully resolved in current commercial markets — bovine-brain PS is not present in current supplements or pet food. Modern soy-lecithin-derived PS and krill-derived PS have established safety records over two decades of human and companion-animal use. Soy-derived PS may carry trace soy-allergen risk for dogs with confirmed soy hypersensitivity; sunflower-lecithin alternatives mitigate this concern. The structural concern at the population level is the marketing-evidence gap (PS marketed for senior wellness applications with the evidence base concentrated on canine CDS specifically) rather than safety. Pet food brands marketing senior cognitive support formulations should clarify whether the formulation is positioned for healthy senior aging (modest evidence) or diagnosed canine cognitive dysfunction syndrome (more robust framework where PS is one component of a structured management plan).
Health risks for your pet
Clinical phosphatidylserine deficiency is not commonly diagnosed in dogs and cats; endogenous synthesis from dietary phosphatidylethanolamine and serine via phosphatidylserine synthase is typically adequate. The clinical framework instead emphasizes therapeutic supplementation in senior cognitive aging concerns and diagnosed CDS: the rationale is mechanistic (age-associated decline in cerebral cortex PS) and supported by modest controlled-trial data (Pan 2010). PS supplementation is generally well tolerated; gastrointestinal upset is the most common side effect at high doses, more commonly reported with soy-lecithin-derived formulations than krill-derived formulations.
PS excess from dietary sources or supplementation is essentially never seen at typical doses (1-3 mg/kg/day in dogs is well tolerated). The structural concern at the population level remains modest evidence base rather than safety. Pet food marketing emphasizing PS in senior formulations produces no acute risk; the clinical relevance depends on the individual senior pet’s cognitive status and the overall management framework. For diagnosed canine CDS, veterinary management combining diet change, environmental enrichment, and complementary supplements is the validated approach; single-ingredient PS supplementation is not a substitute for the structured framework.
What to do if you bought affected product
Pet owners can manage PS decisions through several practical approaches: (1) for senior dogs with cognitive aging concerns or diagnosed canine cognitive dysfunction syndrome (CDS), discuss veterinary-supervised cognitive-support framework with your veterinarian — typical management includes diet change to senior cognitive support formulations (Hill’s b/d, Purina Bright Mind, others), structured environmental enrichment, and complementary supplements (omega-3 EPA/DHA, MCT oil, antioxidants, sometimes PS); (2) for healthy senior dogs without cognitive symptoms, PS supplementation is reasonable but not strongly indicated; commercial senior wellness formulations including PS provide a modest evidence-based component within a broader formulation; (3) for owners of senior cats with cognitive aging signs, the feline cognitive aging evidence base is more limited; discuss with your veterinarian whether PS supplementation is appropriate within the broader feline cognitive support framework; (4) verify PS source-form if soy-allergen concern is in the picture — sunflower-lecithin-derived PS is an alternative for soy-allergen-avoidance formulations; (5) do not pay premium pricing for PS-fortified maintenance diets in young or middle-aged pets — the maintenance indication is not strongly supported for non-senior populations; (6) watch for cognitive aging signs in senior pets — disorientation, altered sleep-wake cycle, loss of house-training, decreased interaction, anxiety changes warrant veterinary evaluation; the diagnostic and management framework for canine CDS continues to develop and structured management produces better outcomes than ad-hoc supplementation alone.
How this affects KibbleIQ’s grade
The KibbleIQ rubric v15 awards modest scoring credit for documented PS inclusion in senior commercial pet food formulations per our published methodology, recognizing manufacturer attention to age-associated cognitive support. The rubric does not weight dose adequacy versus therapeutic range, since pet food PS inclusion typically provides maintenance-range dosing that may or may not produce measurable effect in individual senior animals. The category structurally rewards multi-component senior wellness formulations on this metric, though attributing benefit to PS specifically is difficult given the multi-ingredient confounding. For diagnosed canine cognitive dysfunction syndrome, veterinary-supervised structured management is the validated framework; commercial pet food PS inclusion is at best adjunctive.